Similar articles for PMID: 16157080

Year	Number of Results
1995	2
1996	3
1997	5
1998	2
1999	5
2000	1
2001	7
2002	6
2003	9
2004	7
2005	12
2006	4
2007	2
2008	8
2009	5
2010	3
2011	7
2012	5
2013	2
2015	3
2016	1
2017	3
2018	3
2019	6
2022	1
2024	0

1

The African American Study of Kidney Disease: do these results indicate that 140/90 mm hg is good enough?

Rahman M, El-Meanawy A, Romanello J. Rahman M, et al. Curr Hypertens Rep. 2005 Oct;7(5):363-6. doi: 10.1007/s11906-005-0072-6. Curr Hypertens Rep. 2005. PMID: 16157080 Review.

2

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.

Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study Group. Wright JT Jr, et al. JAMA. 2002 Nov 20;288(19):2421-31. doi: 10.1001/jama.288.19.2421. JAMA. 2002. PMID: 12435255 Clinical Trial.

3

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).

[No authors listed] [No authors listed] Lancet. 1997 Jun 28;349(9069):1857-63. Lancet. 1997. PMID: 9217756 Clinical Trial.

4

Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.

Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER 3rd, Norris K, O'Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT Jr, Xu S; African American Study of Kidney Disease and Hypertension (AASK) Study Group. Agodoa LY, et al. JAMA. 2001 Jun 6;285(21):2719-28. doi: 10.1001/jama.285.21.2719. JAMA. 2001. PMID: 11386927 Clinical Trial.

5

[Slowing the progression of chronic renal insufficiency with captopril in rats with spontaneous arterial hypertension and adriamycin nephropathy].

Jovanović DB, Jovović Dj, Varagić J, Dimitrijević J, Dragojlović Z, Djukanović L. Jovanović DB, et al. Srp Arh Celok Lek. 2002 Mar-Apr;130(3-4):73-80. doi: 10.2298/sarh0204073j. Srp Arh Celok Lek. 2002. PMID: 12154518 Free article. Serbian.

6

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.

Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, de Jong PE, de Zeeuw D, Lau J, Levey AS. Jafar TH, et al. Ann Intern Med. 2001 Jul 17;135(2):73-87. doi: 10.7326/0003-4819-135-2-200107170-00007. Ann Intern Med. 2001. PMID: 11453706

7

The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.

Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, Rostand SG, Miller E, Smith W, Bakris GL. Lea J, et al. Arch Intern Med. 2005 Apr 25;165(8):947-53. doi: 10.1001/archinte.165.8.947. Arch Intern Med. 2005. PMID: 15851648 Clinical Trial.

8

Effect of Blood Pressure Control on Long-Term Risk of End-Stage Renal Disease and Death Among Subgroups of Patients With Chronic Kidney Disease.

Ku E, Sarnak MJ, Toto R, McCulloch CE, Lin F, Smogorzewski M, Hsu CY. Ku E, et al. J Am Heart Assoc. 2019 Aug 20;8(16):e012749. doi: 10.1161/JAHA.119.012749. Epub 2019 Aug 14. J Am Heart Assoc. 2019. PMID: 31411082 Free PMC article.

9

Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.

Ruggenenti P, Perna A, Gherardi G, Benini R, Remuzzi G. Ruggenenti P, et al. Am J Kidney Dis. 2000 Jun;35(6):1155-65. doi: 10.1016/s0272-6386(00)70054-0. Am J Kidney Dis. 2000. PMID: 10845831 Clinical Trial.

10

How Low Do We Go (in the Post-SPRINT Era)?

Burgner A, Lewis JB. Burgner A, et al. Adv Chronic Kidney Dis. 2019 Mar;26(2):110-116. doi: 10.1053/j.ackd.2019.01.007. Adv Chronic Kidney Dis. 2019. PMID: 31023444 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

110 results

Results by year